{"product_id":"trevogrumab-10mg","title":"Trevogrumab (REGN1033 \/ SAR391786) 10mg","description":"\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eDue to the nature of this product being a monoclonal antibody and thus must be manufactured and stored under stringent quality standards, order fulfillment requires additional processing time. Please allow 2–3 weeks for production, plus shipping time, to ensure we deliver a product that meets our quality and purity specifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"68\" data-start=\"0\"\u003eTrevogrumab (REGN1033 \/ SAR391786)\u003c\/h2\u003e\n\u003cp data-end=\"392\" data-start=\"88\"\u003e\u003cstrong data-end=\"103\" data-start=\"88\"\u003eTrevogrumab\u003c\/strong\u003e is a \u003cstrong data-end=\"144\" data-start=\"109\"\u003efully human monoclonal antibody\u003c\/strong\u003e developed by Regeneron (with Sanofi involvement in earlier development) that \u003cstrong data-end=\"255\" data-start=\"222\"\u003eneutralizes myostatin (GDF-8)\u003c\/strong\u003e—a TGF-β superfamily ligand that acts as a \u003cstrong data-end=\"353\" data-start=\"298\"\u003emaster negative regulator of skeletal-muscle growth\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"775\" data-start=\"394\"\u003e\u003cstrong data-end=\"414\" data-start=\"394\"\u003eKey positioning:\u003c\/strong\u003e Unlike broader “activin receptor trap” strategies, trevogrumab is described as \u003cstrong data-end=\"521\" data-start=\"494\"\u003eselective for myostatin\u003c\/strong\u003e(i.e., designed to avoid binding closely related ligands such as \u003cstrong data-end=\"597\" data-start=\"587\"\u003eGDF-11\u003c\/strong\u003e or \u003cstrong data-end=\"613\" data-start=\"601\"\u003eactivins\u003c\/strong\u003e, depending on the source), which matters because broader blockade can increase effect size but may alter safety\/physiology. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"780\" data-start=\"777\"\u003e\n\u003ch3 data-end=\"839\" data-start=\"782\"\u003e2) Why myostatin matters: target biology in one slide\u003c\/h3\u003e\n\u003cp data-end=\"1142\" data-start=\"840\"\u003e\u003cstrong data-end=\"861\" data-start=\"840\"\u003eMyostatin (GDF-8)\u003c\/strong\u003e is secreted predominantly by skeletal muscle and restrains muscle mass via \u003cstrong data-end=\"985\" data-start=\"937\"\u003eActRIIB (activin type II receptor) signaling\u003c\/strong\u003e, activating canonical \u003cstrong data-end=\"1019\" data-start=\"1008\"\u003eSMAD2\/3\u003c\/strong\u003e transcriptional programs that suppress anabolic pathways and promote catabolic tone. Inhibition shifts the balance toward:\u003c\/p\u003e\n\u003cul data-end=\"1319\" data-start=\"1143\"\u003e\n\u003cli data-end=\"1191\" data-start=\"1143\"\u003e\n\u003cp data-end=\"1191\" data-start=\"1145\"\u003e\u003cstrong data-end=\"1191\" data-start=\"1145\"\u003e↑ protein synthesis \/ hypertrophy programs\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1211\" data-start=\"1192\"\u003e\n\u003cp data-end=\"1211\" data-start=\"1194\"\u003e\u003cstrong data-end=\"1211\" data-start=\"1194\"\u003e↓ proteolysis\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1319\" data-start=\"1212\"\u003e\n\u003cp data-end=\"1319\" data-start=\"1214\"\u003e\u003cstrong data-end=\"1256\" data-start=\"1214\"\u003eimproved muscle “anabolic sensitivity”\u003c\/strong\u003e in certain catabolic contexts (aging, immobilization, disease)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1529\" data-start=\"1321\"\u003eThis biology is strongly validated genetically (animals and rare human phenotypes), which is why myostatin has been a long-running drug target for \u003cstrong data-end=\"1490\" data-start=\"1468\"\u003esarcopenia\/frailty\u003c\/strong\u003e, \u003cstrong data-end=\"1504\" data-start=\"1492\"\u003ecachexia\u003c\/strong\u003e, and \u003cstrong data-end=\"1528\" data-start=\"1510\"\u003emuscle wasting\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"1534\" data-start=\"1531\"\u003e\n\u003ch2 data-end=\"1571\" data-start=\"1536\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"1630\" data-start=\"1573\"\u003e3.1 Receptor pharmacodynamics (ligand-level blockade)\u003c\/h3\u003e\n\u003cul data-end=\"2016\" data-start=\"1631\"\u003e\n\u003cli data-end=\"1780\" data-start=\"1631\"\u003e\n\u003cp data-end=\"1780\" data-start=\"1633\"\u003e\u003cstrong data-end=\"1706\" data-start=\"1633\"\u003eTrevogrumab binds circulating (and possibly locally active) myostatin\u003c\/strong\u003e, preventing engagement with \u003cstrong data-end=\"1763\" data-start=\"1735\"\u003eActRIIB\/ALK4\/5 complexes\u003c\/strong\u003e on muscle cells.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2016\" data-start=\"1781\"\u003e\n\u003cp data-end=\"2016\" data-start=\"1783\"\u003eDownstream, reduced myostatin tone decreases \u003cstrong data-end=\"1850\" data-start=\"1828\"\u003eSMAD2\/3 activation\u003c\/strong\u003e, allowing relative dominance of anabolic signals (e.g., mTOR-linked pathways) and reduced expression of atrophy-related transcriptional programs (context-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"2054\" data-start=\"2018\"\u003e3.2 Systems biology consequences\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2582\" data-start=\"2055\"\u003e\n\u003cthead data-end=\"2094\" data-start=\"2055\"\u003e\n\u003ctr data-end=\"2094\" data-start=\"2055\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"2064\" data-start=\"2055\"\u003eDomain\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"2085\" data-start=\"2064\"\u003eExpected direction\u003c\/th\u003e\n\u003cth data-col-size=\"lg\" data-end=\"2094\" data-start=\"2085\"\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2582\" data-start=\"2110\"\u003e\n\u003ctr data-end=\"2192\" data-start=\"2110\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2124\" data-start=\"2110\"\u003eMuscle mass\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2128\" data-start=\"2124\"\u003e↑\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\" data-end=\"2192\" data-start=\"2128\"\u003eMost consistent signal across myostatin blockade approaches.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2367\" data-start=\"2193\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2215\" data-start=\"2193\"\u003eStrength \/ function\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2226\" data-start=\"2215\"\u003evariable\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\" data-end=\"2367\" data-start=\"2226\"\u003eMass gain doesn’t always translate to functional gains—depends on training, neural adaptation, disease context, and endpoint sensitivity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2582\" data-start=\"2368\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2379\" data-start=\"2368\"\u003eFat mass\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2390\" data-start=\"2379\"\u003evariable\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\" data-end=\"2582\" data-start=\"2390\"\u003eSome programs show neutral effects; combined blockade strategies can influence fat mass, especially when paired with GLP-1–based weight loss programs. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2587\" data-start=\"2584\"\u003e\n\u003ch2 data-end=\"2661\" data-start=\"2589\"\u003e4) Pharmacokinetics \u0026amp; exposure engineering (what’s known \/ inferable)\u003c\/h2\u003e\n\u003cp data-end=\"3015\" data-start=\"2662\"\u003eAs a monoclonal antibody, trevogrumab is expected to display \u003cstrong data-end=\"2746\" data-start=\"2723\"\u003etypical IgG-like PK\u003c\/strong\u003e: slow absorption after SC dosing, limited distribution largely to vascular\/interstitial spaces, and clearance via \u003cstrong data-end=\"2895\" data-start=\"2861\"\u003ereticuloendothelial catabolism\u003c\/strong\u003e with \u003cstrong data-end=\"2928\" data-start=\"2901\"\u003eFcRn-mediated recycling\u003c\/strong\u003e contributing to a multi-week half-life (exact values are product- and study-specific).\u003c\/p\u003e\n\u003cp data-end=\"3275\" data-start=\"3017\"\u003eFormal PK descriptions and dose regimens are best taken from trial registries and product-facing clinical documents rather than inferred; clinical programs have used \u003cstrong data-end=\"3214\" data-start=\"3183\"\u003esubcutaneous administration\u003c\/strong\u003e in sarcopenia studies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"3280\" data-start=\"3277\"\u003e\n\u003ch2 data-end=\"3341\" data-start=\"3282\"\u003e5) Clinical development and evidence (what the data say)\u003c\/h2\u003e\n\u003ch3 data-end=\"3401\" data-start=\"3343\"\u003e5.1 Sarcopenia \/ age-related muscle loss (monotherapy)\u003c\/h3\u003e\n\u003cp data-end=\"3591\" data-start=\"3402\"\u003eA completed European trial program (REGN1033) evaluated multiple SC doses over 12 weeks in sarcopenia with \u003cstrong data-end=\"3531\" data-start=\"3509\"\u003eDXA lean body mass\u003c\/strong\u003e as a primary outcome. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"3665\" data-start=\"3593\"\u003eA separate protocol document summarizing prior trevogrumab work reports:\u003c\/p\u003e\n\u003cul data-end=\"3889\" data-start=\"3666\"\u003e\n\u003cli data-end=\"3739\" data-start=\"3666\"\u003e\n\u003cp data-end=\"3739\" data-start=\"3668\"\u003e\u003cstrong data-end=\"3734\" data-start=\"3668\"\u003eLean body mass increased ~2.29% vs placebo at the highest dose\u003c\/strong\u003e, but\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3889\" data-start=\"3740\"\u003e\n\u003cp data-end=\"3889\" data-start=\"3742\"\u003e\u003cstrong data-end=\"3823\" data-start=\"3742\"\u003efunctional endpoints (e.g., 6-minute walk test) did not improve significantly\u003c\/strong\u003e vs placebo in that context. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4156\" data-start=\"3891\"\u003e\u003cstrong data-end=\"3921\" data-start=\"3891\"\u003eScientific interpretation:\u003c\/strong\u003e This is a recurring theme in the myostatin field—\u003cstrong data-end=\"4068\" data-start=\"3971\"\u003ehypertrophy signals are easier to achieve than reliable, clinically meaningful function gains\u003c\/strong\u003e, especially without a standardized exercise\/rehab program and when endpoints are noisy.\u003c\/p\u003e\n\u003chr data-end=\"4161\" data-start=\"4158\"\u003e\n\u003ch3 data-end=\"4239\" data-start=\"4163\"\u003e5.2 “Quality of weight loss” in obesity (combination with GLP-1 therapy)\u003c\/h3\u003e\n\u003cp data-end=\"4512\" data-start=\"4240\"\u003eA major contemporary rationale for trevogrumab has shifted toward \u003cstrong data-end=\"4363\" data-start=\"4306\"\u003epreserving lean mass during GLP-1–induced weight loss\u003c\/strong\u003e, where a meaningful fraction of weight loss can be lean tissue. In Regeneron’s Phase 2 \u003cstrong data-end=\"4462\" data-start=\"4451\"\u003eCOURAGE\u003c\/strong\u003e program (semaglutide ± trevogrumab ± garetosmab):\u003c\/p\u003e\n\u003cul data-end=\"4999\" data-start=\"4513\"\u003e\n\u003cli data-end=\"4634\" data-start=\"4513\"\u003e\n\u003cp data-end=\"4634\" data-start=\"4515\"\u003einterim analyses reported that \u003cstrong data-end=\"4606\" data-start=\"4546\"\u003e~35% of semaglutide-associated weight loss was lean mass\u003c\/strong\u003e in the studied context, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4999\" data-start=\"4635\"\u003e\n\u003cp data-end=\"4999\" data-start=\"4637\"\u003eadding trevogrumab (with or without garetosmab) \u003cstrong data-end=\"4745\" data-start=\"4685\"\u003ehelped preserve lean mass while increasing fat-mass loss\u003c\/strong\u003e at interim evaluation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr\u003eRegeneron later disclosed additional results from COURAGE describing the combination approach as improving body composition outcomes during GLP-1 therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"5330\" data-start=\"5001\"\u003e\u003cstrong data-end=\"5025\" data-start=\"5001\"\u003eMechanistic support:\u003c\/strong\u003e A 2025 \u003cem data-end=\"5050\" data-start=\"5033\"\u003eCell Metabolism\u003c\/em\u003e paper (preclinical + translational framing) discusses \u003cstrong data-end=\"5137\" data-start=\"5105\"\u003eGDF-8 and activin A blockade\u003c\/strong\u003e as a strategy to protect lean mass and improve fat-loss quality alongside GLP-1 receptor agonism, reinforcing the biological plausibility of the approach. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"5335\" data-start=\"5332\"\u003e\n\u003ch3 data-end=\"5392\" data-start=\"5337\"\u003e5.3 Dual-pathway strategies (myostatin + activin A)\u003c\/h3\u003e\n\u003cp data-end=\"5679\" data-start=\"5393\"\u003eTrevogrumab is being studied in combination paradigms with \u003cstrong data-end=\"5466\" data-start=\"5452\"\u003egaretosmab\u003c\/strong\u003e (activin A antibody) in certain settings, including obesity-related body composition research and early-phase work described across trial registries and related publications. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"5948\" data-start=\"5681\"\u003e\u003cstrong data-end=\"5695\" data-start=\"5681\"\u003eRationale:\u003c\/strong\u003e Myostatin blockade primarily drives \u003cstrong data-end=\"5763\" data-start=\"5732\"\u003elean mass gain\/preservation\u003c\/strong\u003e, while activin A blockade may add complementary tissue effects (context-dependent), potentially improving the \u003cstrong data-end=\"5899\" data-start=\"5874\"\u003elean\/fat partitioning\u003c\/strong\u003e of weight change when paired with GLP-1 therapy.\u003c\/p\u003e\n\u003chr data-end=\"5953\" data-start=\"5950\"\u003e\n\u003ch2 data-end=\"6015\" data-start=\"5955\"\u003e6) Safety and tolerability: what to watch mechanistically\u003c\/h2\u003e\n\u003cp data-end=\"6155\" data-start=\"6016\"\u003eBecause trevogrumab is investigational and used in controlled trials, the most defensible safety framing is \u003cstrong data-end=\"6154\" data-start=\"6124\"\u003eclass- and target-informed\u003c\/strong\u003e:\u003c\/p\u003e\n\u003ch3 data-end=\"6217\" data-start=\"6157\"\u003e6.1 Expected \/ plausible risks with myostatin inhibition\u003c\/h3\u003e\n\u003cul data-end=\"6930\" data-start=\"6218\"\u003e\n\u003cli data-end=\"6285\" data-start=\"6218\"\u003e\n\u003cp data-end=\"6285\" data-start=\"6220\"\u003e\u003cstrong data-end=\"6248\" data-start=\"6220\"\u003eInjection-site reactions\u003c\/strong\u003e and typical mAb tolerability issues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6482\" data-start=\"6286\"\u003e\n\u003cp data-end=\"6482\" data-start=\"6288\"\u003e\u003cstrong data-end=\"6326\" data-start=\"6288\"\u003eDisproportionate mass vs function:\u003c\/strong\u003e hypertrophy without commensurate strength\/coordination can matter in frail populations (fall risk is a clinical concern, even if not “caused” by the drug).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6693\" data-start=\"6483\"\u003e\n\u003cp data-end=\"6693\" data-start=\"6485\"\u003e\u003cstrong data-end=\"6528\" data-start=\"6485\"\u003eTendon\/soft tissue adaptation mismatch:\u003c\/strong\u003e rapid changes in muscle force potential could theoretically stress tendons\/entheses if activity increases abruptly (a general musculoskeletal adaptation principle).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6930\" data-start=\"6694\"\u003e\n\u003cp data-end=\"6930\" data-start=\"6696\"\u003e\u003cstrong data-end=\"6730\" data-start=\"6696\"\u003eCardiac muscle considerations:\u003c\/strong\u003e myostatin biology intersects with cardiac remodeling pathways in some models; clinical relevance depends on ligand specificity, exposure, and population risk (requires targeted monitoring in trials).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"6957\" data-start=\"6932\"\u003e6.2 What trials imply\u003c\/h3\u003e\n\u003cp data-end=\"7250\" data-start=\"6958\"\u003eThe sarcopenia experience suggests \u003cstrong data-end=\"7056\" data-start=\"6993\"\u003elean mass can increase without clear functional improvement\u003c\/strong\u003e, which indirectly argues for pairing pharmacology with \u003cstrong data-end=\"7152\" data-start=\"7112\"\u003estructured resistance training\/rehab\u003c\/strong\u003e if the clinical goal is function rather than composition. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"7255\" data-start=\"7252\"\u003e\n\u003ch2 data-end=\"7332\" data-start=\"7257\"\u003e7) Regulatory landscape (as of the most recent public information found)\u003c\/h2\u003e\n\u003cul data-end=\"7666\" data-start=\"7333\"\u003e\n\u003cli data-end=\"7447\" data-start=\"7333\"\u003e\n\u003cp data-end=\"7447\" data-start=\"7335\"\u003e\u003cstrong data-end=\"7374\" data-start=\"7335\"\u003eTrevogrumab remains investigational\u003c\/strong\u003e (no FDA\/EMA marketing authorization found in the sources reviewed here).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7666\" data-start=\"7448\"\u003e\n\u003cp data-end=\"7666\" data-start=\"7450\"\u003eIts development focus appears to have evolved from sarcopenia monotherapy toward \u003cstrong data-end=\"7625\" data-start=\"7531\"\u003ecombination regimens aimed at improving body composition during GLP-1–mediated weight loss\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7671\" data-start=\"7668\"\u003e\n\u003ch2 data-end=\"7740\" data-start=\"7673\"\u003e8) How trevogrumab fits into the broader “muscle drug” landscape\u003c\/h2\u003e\n\u003ch3 data-end=\"7786\" data-start=\"7742\"\u003e8.1 Why the field struggled historically\u003c\/h3\u003e\n\u003cp data-end=\"7894\" data-start=\"7787\"\u003eMany myostatin\/ActRIIB strategies produced \u003cstrong data-end=\"7860\" data-start=\"7830\"\u003eimpressive lean mass gains\u003c\/strong\u003e but inconsistent improvements in:\u003c\/p\u003e\n\u003cul data-end=\"8037\" data-start=\"7895\"\u003e\n\u003cli data-end=\"7911\" data-start=\"7895\"\u003e\n\u003cp data-end=\"7911\" data-start=\"7897\"\u003e\u003cstrong data-end=\"7911\" data-start=\"7897\"\u003egait speed\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7922\" data-start=\"7912\"\u003e\n\u003cp data-end=\"7922\" data-start=\"7914\"\u003e\u003cstrong data-end=\"7922\" data-start=\"7914\"\u003e6MWT\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7940\" data-start=\"7923\"\u003e\n\u003cp data-end=\"7940\" data-start=\"7925\"\u003e\u003cstrong data-end=\"7940\" data-start=\"7925\"\u003echair-stand\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7955\" data-start=\"7941\"\u003e\n\u003cp data-end=\"7955\" data-start=\"7943\"\u003e\u003cstrong data-end=\"7955\" data-start=\"7943\"\u003ehandgrip\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8037\" data-start=\"7956\"\u003e\n\u003cp data-end=\"8037\" data-start=\"7958\"\u003e\u003cstrong data-end=\"7987\" data-start=\"7958\"\u003epatient-reported function\u003c\/strong\u003e\u003cbr\u003e…especially in heterogeneous elderly populations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"8260\" data-start=\"8039\"\u003eThis is why newer programs increasingly frame muscle agents as \u003cstrong data-end=\"8114\" data-start=\"8102\"\u003eadjuncts\u003c\/strong\u003e (rehab, GLP-1 therapies, post-hospitalization recovery, etc.) rather than stand-alone “sarcopenia cures.” \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"8294\" data-start=\"8262\"\u003e8.2 The “GLP-1 era” re-frame\u003c\/h3\u003e\n\u003cp data-end=\"8359\" data-start=\"8295\"\u003eWith high-efficacy obesity drugs, the clinical question becomes:\u003c\/p\u003e\n\u003cblockquote data-end=\"8443\" data-start=\"8360\"\u003e\n\u003cp data-end=\"8443\" data-start=\"8362\"\u003eCan we maintain or increase fat loss \u003cstrong data-end=\"8442\" data-start=\"8399\"\u003ewhile protecting lean mass and function\u003c\/strong\u003e?\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003cp data-end=\"8624\" data-start=\"8445\"\u003eCOURAGE represents exactly that reframing, positioning trevogrumab as a \u003cstrong data-end=\"8547\" data-start=\"8517\"\u003ebody-composition optimizer\u003c\/strong\u003e rather than a pure “muscle builder.” \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"8629\" data-start=\"8626\"\u003e\n\u003ch2 data-end=\"8681\" data-start=\"8631\"\u003e9) Future directions and high-value experiments\u003c\/h2\u003e\n\u003cp data-end=\"8791\" data-start=\"8682\"\u003eIf you want trevogrumab’s story to become truly “clinical-grade,” these are the pivotal scientific questions:\u003c\/p\u003e\n\u003col data-end=\"9501\" data-start=\"8793\"\u003e\n\u003cli data-end=\"8978\" data-start=\"8793\"\u003e\n\u003cp data-end=\"8978\" data-start=\"8796\"\u003e\u003cstrong data-end=\"8858\" data-start=\"8796\"\u003eDoes lean-mass preservation translate into better function\u003c\/strong\u003e during GLP-1 therapy?\u003cbr data-end=\"8883\" data-start=\"8880\"\u003eEndpoints: strength (isokinetic), power, VO₂peak, stair climb, falls, frailty indices, PROs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9167\" data-start=\"8980\"\u003e\n\u003cp data-end=\"9167\" data-start=\"8983\"\u003e\u003cstrong data-end=\"9030\" data-start=\"8983\"\u003eBody composition quality with hard outcomes\u003c\/strong\u003e\u003cbr data-end=\"9033\" data-start=\"9030\"\u003eDoes preserving lean mass reduce \u003cstrong data-end=\"9106\" data-start=\"9069\"\u003eweight-loss–associated sarcopenia\u003c\/strong\u003e, improve \u003cstrong data-end=\"9134\" data-start=\"9116\"\u003emetabolic rate\u003c\/strong\u003e, and sustain weight maintenance?\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9321\" data-start=\"9169\"\u003e\n\u003cp data-end=\"9321\" data-start=\"9172\"\u003e\u003cstrong data-end=\"9198\" data-start=\"9172\"\u003eMechanistic biomarkers\u003c\/strong\u003e\u003cbr data-end=\"9201\" data-start=\"9198\"\u003eSMAD2\/3 pathway signatures, muscle protein synthesis markers, imaging (MRI muscle volume), neuromuscular performance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9501\" data-start=\"9323\"\u003e\n\u003cp data-end=\"9501\" data-start=\"9326\"\u003e\u003cstrong data-end=\"9350\" data-start=\"9326\"\u003ePopulation selection\u003c\/strong\u003e\u003cbr data-end=\"9353\" data-start=\"9350\"\u003eOlder adults on GLP-1 therapy, post-hospitalization patients, or those with low baseline muscle reserves may derive the highest marginal benefit.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"9506\" data-start=\"9503\"\u003e\n\u003ch2 data-end=\"9557\" data-start=\"9508\"\u003eSelected references (most directly supportive)\u003c\/h2\u003e\n\u003cul data-end=\"10287\" data-start=\"9558\"\u003e\n\u003cli data-end=\"9669\" data-start=\"9558\"\u003e\n\u003cp data-end=\"9669\" data-start=\"9560\"\u003ePhase 2 sarcopenia trial record (REGN1033, DXA lean mass endpoint): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9781\" data-start=\"9670\"\u003e\n\u003cp data-end=\"9781\" data-start=\"9672\"\u003eClinical trial registry entry for sarcopenia program (NCT01963598): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9908\" data-start=\"9782\"\u003e\n\u003cp data-end=\"9908\" data-start=\"9784\"\u003eProtocol summary noting lean mass gain without significant functional improvement: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10061\" data-start=\"9909\"\u003e\n\u003cp data-end=\"10061\" data-start=\"9911\"\u003eCOURAGE interim results (semaglutide lean mass loss proportion; preservation with trevogrumab ± garetosmab): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10149\" data-start=\"10062\"\u003e\n\u003cp data-end=\"10149\" data-start=\"10064\"\u003eCOURAGE full\/updated results press release: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10287\" data-start=\"10150\"\u003e\n\u003cp data-end=\"10287\" data-start=\"10152\"\u003e\u003cem data-end=\"10169\" data-start=\"10152\"\u003eCell Metabolism\u003c\/em\u003e 2025 mechanistic\/translational paper on GDF8\/activin A blockade with GLP-1:\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684843024722,"sku":null,"price":6500.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/trevogrumab_10mg.png?v=1770834809","url":"https:\/\/sciencepeptideslab.com\/products\/trevogrumab-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}